Study Identifies Mitochondrial Plaques in Alzheimer’s Brains, Affecting 57 Million People
Updated
Updated · ScienceAlert · Aug 3
Study Identifies Mitochondrial Plaques in Alzheimer’s Brains, Affecting 57 Million People
2 articles · Updated · ScienceAlert · Aug 3
Summary
Nature Neuroscience researchers found mitochondrial plaques in postmortem Alzheimer’s brains and engineered mice, identifying a previously unrecognized disease feature absent in age-matched healthy controls.
Direct mitophagy measurements linked the plaques to failed recycling of damaged mitochondria, with acidic and neutral mitochondrial debris building up as lysosomes could not keep pace.
In mice, plaque aggregation appeared by 15 weeks and intensified by 50–60 weeks; the deposits formed alone or alongside amyloid-beta and became more spatially mixed as disease progressed.
The plaques appeared within neuronal neurites rather than outside cells, suggesting a direct hit to signal-transmitting structures and a potential diagnostic marker and treatment target.
The findings may help explain why clearing amyloid alone has not stopped neurodegeneration, supporting combination therapies that target both amyloid-beta and mitochondrial buildup.
If mitochondrial plaques appear early in Alzheimer’s, how soon could doctors detect and target them in living patients?
Unveiling Mitochondrial Plaques: How a 2026 Discovery is Transforming Alzheimer’s Disease Research and Care
Overview
In July 2026, scientists discovered mitochondrial plaques—new intracellular structures that form inside neurons in Alzheimer’s disease. These plaques arise when the cell’s waste-clearance systems fail, causing damaged mitochondria and amyloid precursor protein to pile up and coalesce, which severely impairs the neuron’s energy production and survival. Mitochondrial plaques appear early, even before classic amyloid plaques, and may act as seeds that accelerate broader brain damage. Genetic risk factors like APOE4 worsen this process by disrupting mitochondrial function and lipid metabolism. This breakthrough explains why traditional therapies targeting only extracellular plaques have limited success and highlights the importance of early detection, metabolic therapies, and lifestyle interventions to protect brain health.